The test is designed to determine which early-stage, estrogen receptor-positive breast cancer patients are likely to benefit from extended endocrine therapy.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The diagnostics company reported organic sales increased 4 percent in Q4 and 7 percent in 2015, and set a growth target of 6 percent to 8 percent for 2016.
The molecular diagnostics developer will use the money to continue expanding its commercial presence in the cancer diagnostics market.
The companies will investigate the feasibility of using BioTheranostics’ proprietary biomarkers and DeNovos CTC platform for blood-based diagnostics.
NEW YORK (GenomeWeb) – BioTheranostics today said that it has received a positive coverage and reimbursement evaluation from a Medicare contractor for its Breast Cancer Index test.
BioTheranostics Nicolas Barthelemy its new president and CEO. He succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux.
Originally published Sept. 22.
Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.
Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.
Japan is to release rules governing some gene-edited food, according to NHK World.
In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.